CA-IL12

**CA-IL12** is an investigational **cell therapy** from **Cytonus Therapeutics** based on the company's enucleated **Cargocyte** platform and designed to localize delivery of **interleukin-12** within tumor tissue. Public company materials describe CA-IL12 as engineered Cargocytes that infiltrate solid tumors and synthesize or release a proprietary IL-12 construct at the disease site, with preclinical work focused particularly on **triple-negative breast cancer** and other **immune checkpoint inhibitor-resistant metastatic cancers**. Mechanistically, the product is intended to provide localized IL-12 signaling in the tumor microenvironment, thereby promoting antitumor immune activation while reducing systemic exposure relative to conventional IL-12 administration. Available public information indicates a **preclinical** development stage, with origin linked to **University of California San Diego** and Cytonus' broader off-the-shelf biologic delivery platform.

Other names

Cargocyte IL-12